The data published in NEJM highlight the positive Phase 3 VALIANT results at Week 26, which were consistent across adolescent and adult patients with C3G and primary IC-MPGN, including patients with ...
Versus Systems Inc. ("Versus" or the "Company") today announced a new initiative with LiftMedia LDA., to leverage Versus Systems' proprietary interactive engagement tools within Digital Out-of-Home ...
ProMIS Neurosciences Inc. , a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics and vaccines targeting toxic misfolded proteins in ...
SHELTON, CONNECTICUT / ACCESS Newswire / December 1, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the ...
Pharmaceutical Technology on MSN
Regeneron and Tessera join forces to forge in vivo AATD gene therapy
If approved, Regeneron and Tessera's TSRA-196 could become the first curative therapy to reach patients with AATD, who have ...
This study presents a large, systematically curated catalog of non-canonical open reading frames (ncORFs) in human and mouse by reanalyzing nearly 400 Ribo-seq datasets using a standardized pipeline; ...
In a statement, Denmark-based Lundbeck said it had carried out a "comprehensive assessment" of the bids on the table for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback